MZE-829 is under clinical development by Maze Therapeutics and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase I drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MZE-829’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MZE-829 overview

MZE-829 is under development for the treatment of chronic kidney disease. It acts by targeting APOL1 (apolipoprotein L1) and is administered through oral route.

Maze Therapeutics overview

Maze Therapeutics (Maze) is a biotechnology company that focused on translating novel genetic insights into new medicines. It is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines. Maze translates novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. The Company serves customers in the State of California. Maze is headquartered in South San Francisco, California, the US.

For a complete picture of MZE-829’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.